Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | IL1B | P01584 | 7/20 | 0.46 |
| ▸ | TNF | P01375 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181078 | 1.00 | NLRP3 (0.74) | NLRP3KCNH2IL1BTNFCHEK1 | |
| SCHEMBL26435098 | 1.00 | NLRP3 (0.74) | NLRP3KCNH2IL1BTNFCHEK1 | |
| SCHEMBL30624986 | 1.00 | NLRP3 (0.74) | NLRP3KCNH2IL1BTNFCHEK1 | |
| SCHEMBL30181196 | 1.00 | NLRP3 (0.74) | NLRP3KCNH2IL1BTNFCHEK1 | |
| SCHEMBL24855438 | 1.00 | NLRP3 (0.74) | NLRP3KCNH2IL1BTNFCHEK1 | |
| SCHEMBL30356551 | 1.00 | NLRP3 (0.74) | NLRP3KCNH2IL1BTNFCHEK1 | |
| SCHEMBL24855439 | 1.00 | NLRP3 (0.74) | NLRP3KCNH2IL1BTNFCHEK1 | |
| SCHEMBL24855753 | 1.00 | NLRP3 (0.74) | NLRP3KCNH2IL1BTNFCHEK1 | |
| SCHEMBL24855752 | 1.00 | NLRP3 (0.74) | NLRP3KCNH2IL1BTNFCHEK1 | |
| SCHEMBL24855754 | 0.99 | NLRP3 (0.73) | NLRP3KCNH2IL1BTNFCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363406-B1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | claimed |
| EP-4363406-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2024-05-08 | — | — | EP | claimed |
| CN-117580826-A | NLRP3 inflammation corpuscle inhibitor | 阿斯利康(瑞典)有限公司 | 2024-02-20 | — | — | CN | claimed |
| WO-2023275366-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2023-01-05 | — | — | WO | claimed |
| US-12503445-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2025-12-23 | — | — | US | disclosed |
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4363406-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2024-05-08 | — | — | EP | disclosed |
| US-11970463-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2024-04-30 | — | — | US | disclosed |
| CN-117580826-A | NLRP3 inflammation corpuscle inhibitor | 阿斯利康(瑞典)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230110122-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-04-13 | — | — | US | disclosed |
| WO-2023275366-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110122-A1 | COMPOUNDS AND THEIR USE | NLRP3, PYCARD, NLRP1 | NLRP3 1/4885KCNH2 3499/4885IL1B 7/4885 |
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | NLRP3, PYCARD, NLRP1 | NLRP3 1/4885KCNH2 3499/4885IL1B 7/4885 |
| US-11970463-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | NLRP3 1/4885KCNH2 3499/4885IL1B 7/4885 |
| US-12503445-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | NLRP3 1/4885KCNH2 3499/4885IL1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.